Michael R. Megna - 04 Oct 2025 Form 4 Insider Report for Kiniksa Pharmaceuticals International, plc (KNSA)

Role
CHIEF ACCOUNTING OFFICER
Signature
/s/ Douglas Barry, Attorney-in-Fact
Issuer symbol
KNSA
Transactions as of
04 Oct 2025
Net transactions value
-$3,272
Form type
4
Filing time
08 Oct 2025, 16:58:18 UTC
Previous filing
03 Sep 2025
Next filing
22 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Megna Michael R CHIEF ACCOUNTING OFFICER 23 OLD BOND STREET, THIRD FLOOR, LONDON, UNITED KINGDOM /s/ Douglas Barry, Attorney-in-Fact 08 Oct 2025 0001464583

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Ordinary Share Options Exercise +175 +0.46% 38,186 04 Oct 2025 Direct F1
transaction KNSA Class A Ordinary Share Tax liability $3,272 -85 -0.22% $38.49 38,101 04 Oct 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Restricted Share Unit Options Exercise $0 -175 -100% $0.000000 0 04 Oct 2025 Class A Ordinary Share 175 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F2 The RSUs vest over a four year period, with 25% of the RSUs vesting on each anniversary of the date of grant, October 4, 2021.